Michael Gold to Anti-Arrhythmia Agents
This is a "connection" page, showing publications Michael Gold has written about Anti-Arrhythmia Agents.
Connection Strength
1.440
-
The effect of procainamide on T wave alternans. J Cardiovasc Electrophysiol. 1999 May; 10(5):649-54.
Score: 0.151
-
Intravenous amiodarone suppression of electrical storm refractory to chronic oral amiodarone. Pacing Clin Electrophysiol. 1999 Apr; 22(4 Pt 1):665-7.
Score: 0.150
-
Comparison of class Ia/Ib versus class III antiarrhythmic drugs for the suppression of inducible sustained ventricular tachycardia associated with coronary artery disease. Am J Cardiol. 1997 Sep 01; 80(5):591-4.
Score: 0.135
-
Lidocaine-related increase in defibrillation threshold. Anesth Analg. 1997 Aug; 85(2):299-300.
Score: 0.134
-
Efficacy and safety of procainamide in preventing arrhythmias after coronary artery bypass surgery. Am J Cardiol. 1996 Nov 01; 78(9):975-9.
Score: 0.127
-
Electrophysiologic effects and predictors of success of combination therapy with class Ia and Ib antiarrhythmic drugs for sustained ventricular arrhythmias. Am J Cardiol. 1996 Jul 01; 78(1):47-50.
Score: 0.124
-
Use-dependent block of atrial sodium current by ethylisopropylamiloride. J Cardiovasc Pharmacol. 1991 May; 17(5):792-9.
Score: 0.087
-
The effect of dofetilide on ventricular defibrillation thresholds. Pacing Clin Electrophysiol. 2009 Jan; 32(1):24-8.
Score: 0.074
-
Use of traditional and biventricular implantable cardiac devices for primary and secondary prevention of sudden death. Cardiol Clin. 2008 Aug; 26(3):419-31, vi-vii.
Score: 0.072
-
Seasonal variation of mortality in the Antiarrhythmics Versus Implantable Defibrillators (AVID) study registry. Heart Rhythm. 2004 Oct; 1(4):435-40.
Score: 0.055
-
T wave alternans for ventricular arrhythmia risk stratification. Curr Opin Cardiol. 2003 Jan; 18(1):1-5.
Score: 0.049
-
Effects of selective autonomic blockade on T-wave alternans in humans. Circulation. 2002 Feb 19; 105(7):837-42.
Score: 0.046
-
Clinical experience with a dual-chamber implantable cardioverter defibrillator to treat atrial tachyarrhythmias. J Cardiovasc Electrophysiol. 2001 Nov; 12(11):1247-53.
Score: 0.045
-
Electrical storm presages nonsudden death: the antiarrhythmics versus implantable defibrillators (AVID) trial. Circulation. 2001 Apr 24; 103(16):2066-71.
Score: 0.043
-
Lead- and device-related complications in the antiarrhythmics versus implantable defibrillators trial. Am Heart J. 2001 Jan; 141(1):92-8.
Score: 0.042
-
Clinical predictors of transvenous defibrillation energy requirements. Am J Cardiol. 1997 Jan 15; 79(2):150-3.
Score: 0.032
-
Increased Monday incidence of life-threatening ventricular arrhythmias. Experience with a third-generation implantable defibrillator. Circulation. 1996 Sep 15; 94(6):1346-9.
Score: 0.031
-
Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study. J Am Coll Cardiol. 2007 Sep 18; 50(12):1150-7.
Score: 0.017
-
Serial evaluation of atrial tachyarrhythmia burden and frequency after implantation of a dual-chamber cardioverter-defibrillator. J Cardiovasc Electrophysiol. 2005 Jul; 16(7):708-13.
Score: 0.014
-
Effect of implantable defibrillators on arrhythmic events and mortality in the multicenter unsustained tachycardia trial. Circulation. 2002 Jul 09; 106(2):233-8.
Score: 0.012